Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03830567 · ClinicalTrials.gov registry record
Pharmacists Expand Access to Reproductive heaLthcare
A clinical trial, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- 471
- Enrollment target
NCT03830567: Completed study, sponsored by Oregon Health and Science University.
NCT03830567 is a clinical trial that has completed, run by Oregon Health and Science University. The registered enrollment target is 471 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03830567 has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- 471 participants
- Enrollment target
Study Summary
Prospective cohort study of women presenting to initiate hormonal contraception, prescribed by a clinician or pharmacist. Women will be followed for one year to assess contraceptive continuation and unintended pregnancy rates, as well as measures of safety and acceptability.
Primary Outcome
Percentage of contraceptive continuation assessed through survey at 12 months among women who present for contraception in pharmacies.
Interventions
- OTHER Pharmacist prescription
- OTHER Clinician prescription
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Start Date | 2019-01-27 |
| Est. Completion | 2022-02-28 |
What the finished NCT03830567 record still lists
NCT03830567 is an observational study that tracks outcomes without assigning an intervention. The registered 471 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Pharmacist prescription is the first listed.
NCT03830567 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03830567 about?
NCT03830567 is a clinical study titled "Pharmacists Expand Access to Reproductive heaLthcare". Prospective cohort study of women presenting to initiate hormonal contraception, prescribed by a clinician or pharmacist. Women will be followed for one year to assess contraceptive continuation and unintended pregnancy rates, as well as measures of safety and acceptability.
What is the current status of trial NCT03830567?
This trial is currently completed. The enrollment target is 471 participants. The study started on 2019-01-27. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT03830567?
The interventions under investigation include: Pharmacist prescription (OTHER), Clinician prescription (OTHER).
Who is sponsoring clinical trial NCT03830567?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03010150 · 471 participants
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
- NCT05201404 · 471 participants · Phase 3
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
- NCT06375083 · 472 participants · Phase 2
Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression
- NCT06947187 · 472 participants · NA
Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI